KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Esperion Therapeutics (ESPR) EBITDA Margin: 2019-2025

Historic EBITDA Margin for Esperion Therapeutics (ESPR) over the last 7 years, with Sep 2025 value amounting to -35.89%.

  • Esperion Therapeutics' EBITDA Margin rose 2129.00% to -35.89% in Q3 2025 from the same period last year, while for Sep 2025 it was -34.84%, marking a year-over-year decrease of 547.00%. This contributed to the annual value of -15.57% for FY2024, which is 16430.00% up from last year.
  • Esperion Therapeutics' EBITDA Margin amounted to -35.89% in Q3 2025, which was down 132.34% from -15.45% recorded in Q2 2025.
  • Over the past 5 years, Esperion Therapeutics' EBITDA Margin peaked at 44.30% during Q1 2024, and registered a low of -1,139.82% during Q1 2021.
  • In the last 3 years, Esperion Therapeutics' EBITDA Margin had a median value of -62.24% in 2025 and averaged -89.51%.
  • Its EBITDA Margin has fluctuated over the past 5 years, first skyrocketed by 311,360bps in 2021, then crashed by 24,480bps in 2022.
  • Quarterly analysis of 5 years shows Esperion Therapeutics' EBITDA Margin stood at -423.02% in 2021, then spiked by 12,865bps to -294.38% in 2022, then surged by 11,967bps to -174.71% in 2023, then surged by 14,386bps to -30.85% in 2024, then surged by 2,129bps to -35.89% in 2025.
  • Its last three reported values are -35.89% in Q3 2025, -15.45% for Q2 2025, and -62.24% during Q1 2025.